| Name | Title | Contact Details |
|---|---|---|
Greg Troiano |
Chief Manufacturing Officer and Senior Vice President of Technical Operations | Profile |
Frank DeRosa |
Chief Technology Officer | Profile |
The FidoCure® team is committed to introducing the therapies that have been successfully used to treat humans with cancer into the world of veterinary medicine. Currently, cancer care for dogs lags behind human cancer care by about 20 years. Our goal is to improve the outcome for canine cancer patients. We are the first and only company to offer the information needed to work with your veterinarian on targeted medicines for dogs with cancer.
Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.
Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.
Cytonome is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.